A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

Morgan Stanley identifies 15 stocks with potential near-term catalysts for growth, offering insights on upcoming earnings and ...

Morgan Stanley (NYSE:MS) expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.